CME Group Inc (CME)vsNovartis AG ADR (NVS)
CME
CME Group Inc
$281.25
-1.95%
FINANCIAL SERVICES · Cap: $101.91B
NVS
Novartis AG ADR
$146.03
+0.44%
HEALTHCARE · Cap: $277.42B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 739% more annual revenue ($56.58B vs $6.74B). CME leads profitability with a 63.3% profit margin vs 23.9%. NVS appears more attractively valued with a PEG of 2.59. CME earns a higher WallStSmart Score of 65/100 (C+).
CME
Buy65
out of 100
Grade: C+
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CME.
Margin of Safety
-51.8%
Fair Value
$110.12
Current Price
$146.03
$35.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 63 of every $100 in revenue as profit
Strong operational efficiency at 69.8%
Large-cap with strong market position
Conservative balance sheet, low leverage
Earnings expanding 21.3% YoY
Generating 1.2B in free cash flow
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : CME
The strongest argument for CME centers on Profit Margin, Operating Margin, Market Cap. Profitability is solid with margins at 63.3% and operating margin at 69.8%. Revenue growth of 14.4% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : CME
The primary concerns for CME are Piotroski F-Score, PEG Ratio.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
CME profiles as a mature stock while NVS is a declining play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
CME is growing revenue faster at 14.4% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
CME scores higher overall (65/100 vs 51/100), backed by strong 63.3% margins and 14.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CME Group Inc
FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA
CME Group Inc. (Chicago Mercantile Exchange, Chicago Board of Trade, New York Mercantile Exchange, The Commodity Exchange) is an American global markets company. It is the world's largest financial derivatives exchange, and trades in asset classes that include agricultural products, currencies, energy, interest rates, metals, stock indexes and cryptocurrencies futures.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other FINANCIAL DATA & STOCK EXCHANGES Stocks
Want to dig deeper into these stocks?